AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22351891 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir and amoxicillin/clavulanate (post-CPG)
Number of subjects: 1033
Study 22351891 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effect of CPG and ASP
Number of subjects: 1033
Study 22351891 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment failure
Number of subjects: 1033
Study 19483319 — intervention group
Group type: EXPERIMENTAL
Intervention: Kampo preparation, byakkokaninjinto (TJ‐34)
Number of subjects: 20
Study 17502824 — intervention group
Group type: EXPERIMENTAL
Intervention: Postortho‐k uncorrected VA in the better eye with 90% contrast: 0.00 ± 0.11
Number of subjects: 31
Study 17502824 — intervention group
Group type: EXPERIMENTAL
Intervention: Postortho‐k uncorrected VA in the better eye with 48% contrast: 0.08 ± 0.11
Number of subjects: 31
Study 17502824 — intervention group
Group type: EXPERIMENTAL
Intervention: Postortho‐k uncorrected VA in the better eye with 21% contrast: 0.21 ± 0.12
Number of subjects: 31
Study 17502824 — intervention group
Group type: EXPERIMENTAL
Intervention: Postortho‐k uncorrected VA in the better eye with 7% contrast: 0.46 ± 0.13
Number of subjects: 31
Study 17502824 — intervention group
Group type: EXPERIMENTAL
Intervention: Postortho‐k VA improvement in the better eye after correction of residual refractive error: improved by 0.07 to 0.12 log units
Number of subjects: 31
Study 17502824 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean percentage reduction in spherical equivalent in better eye: 92% ± 11%
Number of subjects: 31
Study 17502824 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean percentage reduction in spherical equivalent in worse eye: 84% ± 14%
Number of subjects: 31
Study 15181947 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial cement punch pressurizer
Number of subjects: 15
Study 15181947 — intervention group
Group type: COMPARATOR
Intervention: Control (no tibial cement punch pressurizer)
Number of subjects: 15
Study 12377966 — intervention group
Group type: EXPERIMENTAL
Intervention: G17DT 250 micro g
Number of subjects: 30
Study 12377966 — intervention group
Group type: EXPERIMENTAL
Intervention: G17DT 100 micro g
Number of subjects: 30
Study 12377966 — intervention group
Group type: EXPERIMENTAL
Intervention: G17DT (both doses)
Number of subjects: 30
Study 9881078 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cell transplantation (PBSCT)
Number of subjects: 0
Study 9881078 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of salvage therapy and high dose chemo(radio)‐therapy with stem cell support
Number of subjects: 0
Study 7707174 — intervention group
Group type: EXPERIMENTAL
Intervention: 72-hour TPN line changes
Number of subjects: 279
Study 7707174 — intervention group
Group type: COMPARATOR
Intervention: 24-hour TPN line changes
Number of subjects: 279
Study 2528039 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherectomy procedures
Number of subjects: 0
Study 2528039 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 0
Study 2528039 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass operation
Number of subjects: 0
Study 338256 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (mean 1.3 mg/day, doses varied from 1 mg on alternate days to 3 mg daily)
Number of subjects: 10
Study 338256 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (mean 72 mg/day, doses varied from 40 mg on alternate days to 160 mg daily)
Number of subjects: 10
Study 30897068 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral spironolactone (SPRL)
Number of subjects: 50
Study 30897068 — intervention group
Group type: COMPARATOR
Intervention: Half-dose photodynamic therapy
Number of subjects: 50
Study 29652086 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 196
Study 29652086 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 196
Study 29652086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 196
Study 29652086 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment after open surgery
Number of subjects: 196
Study 29652086 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment after EVLA
Number of subjects: 196
Study 29652086 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment after UGFS
Number of subjects: 196
Study 29652086 — intervention group
Group type: EXPERIMENTAL
Intervention: UGFS without further GSV treatment
Number of subjects: 196
Study 28471726 — intervention group
Group type: EXPERIMENTAL
Intervention: blended cognitive behavior therapy (bCBT)
Number of subjects: 88
Study 28471726 — intervention group
Group type: COMPARATOR
Intervention: care as usual (CAU)
Number of subjects: 88
Study 25297344 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 18
Study 23924050 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.3 mg/24 h rivastigmine patch
Number of subjects: 716
Study 23924050 — intervention group
Group type: COMPARATOR
Intervention: 4.6 mg/24 h rivastigmine patch
Number of subjects: 716
Study 21981455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous phenylephrine (PE) infusion
Number of subjects: 8
Study 21981455 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 19067814 — intervention group
Group type: EXPERIMENTAL
Intervention: Redo transseptal puncture (TSP)
Number of subjects: 42
Study 19067814 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult redo TSP
Number of subjects: 42
Study 19067814 — intervention group
Group type: EXPERIMENTAL
Intervention: Fossa ovalis (FO) thickness
Number of subjects: 42
Study 16842692 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI group
Number of subjects: 47
Study 16842692 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI group (dementia patients)
Number of subjects: 47
Study 16842692 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessment
Number of subjects: 47
Study 16842692 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE, WMS, WHO-BCAI
Number of subjects: 47
Study 14601849 — intervention group
Group type: EXPERIMENTAL
Intervention: BSS Plus (n=20)
Number of subjects: 40
Study 14601849 — intervention group
Group type: COMPARATOR
Intervention: Fortified BSS (n=20)
Number of subjects: 40
Study 10966544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilsicainide 150 mg/day for 4 weeks before electrical cardioversion
Number of subjects: 62
Study 10966544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilsicainide 150 mg/day after successful cardioversion
Number of subjects: 62
Study 10966544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 8888359 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (0.15 mg/kg, i.v.)
Number of subjects: 10
Study 8888359 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine (0.5 mg/kg)
Number of subjects: 10
Study 8888359 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 1310889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial cisplatin (150 mg intravenously every 21 days for 2 doses) administered concomitant with radiation therapy
Number of subjects: 33
Study 1310889 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial cisplatin (150 mg intravenously every 21 days for 2 doses) administered sequentially with radiation therapy
Number of subjects: 33
Study 1310889 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant treatment arm
Number of subjects: 33
Study 1310889 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy arm
Number of subjects: 33
Study 1310889 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapeutic courses
Number of subjects: 33
Study 6380363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime plus metronidazole (1.5 g cefuroxime plus 500 mg metronidazole)
Number of subjects: 60
Study 6380363 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole alone (500 mg metronidazole)
Number of subjects: 60
Study 31636065 — intervention group
Group type: EXPERIMENTAL
Intervention: GLS4 120 mg with ritonavir 100 mg
Number of subjects: 0
Study 31636065 — intervention group
Group type: COMPARATOR
Intervention: GLS4 alone (multiple dosing)
Number of subjects: 0
Study 31636065 — intervention group
Group type: COMPARATOR
Intervention: GLS4 240 mg with ritonavir 100 mg (placebo control)
Number of subjects: 0
Study 31636065 — intervention group
Group type: EXPERIMENTAL
Intervention: GLS4 240 mg (single and multiple doses)
Number of subjects: 0
Study 30149375 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice exercises with water resistance therapy at 4 and 8 cm of water depth
Number of subjects: 30
Study 30149375 — intervention group
Group type: COMPARATOR
Intervention: Voice exercises with vowel [a:]
Number of subjects: 30
Study 30149375 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice exercises with water resistance therapy at 8 cm
Number of subjects: 30
Study 26267328 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg selenium daily for 8 weeks
Number of subjects: 64
Study 26651469 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based indoor tanning intervention
Number of subjects: 186
Study 26651469 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 186
Study 23241823 — intervention group
Group type: EXPERIMENTAL
Intervention: VSSL (LigaSure Small Jaw Instrument)
Number of subjects: 40
Study 23241823 — intervention group
Group type: COMPARATOR
Intervention: CTL (Conventional Technique)
Number of subjects: 40
Study 21962066 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy
Number of subjects: 14
Study 21962066 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography
Number of subjects: 14
Study 18469235 — intervention group
Group type: EXPERIMENTAL
Intervention: Salatrim meal
Number of subjects: 22
Study 18469235 — intervention group
Group type: COMPARATOR
Intervention: Traditional fat meal
Number of subjects: 22
Study 18469235 — intervention group
Group type: COMPARATOR
Intervention: Salatrim meal and Traditional fat meal
Number of subjects: 22
Study 16496951 — intervention group
Group type: COMPARATOR
Intervention: Probiotics and synbiotics
Number of subjects: 0
Study 14687451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen/pseudoephedrine modified-release capsule (600 mg ibuprofen + 90 mg pseudoephedrine)
Number of subjects: 0
Study 14687451 — intervention group
Group type: COMPARATOR
Intervention: Standard formulations of ibuprofen (400 mg) and pseudoephedrine (60 mg)
Number of subjects: 0
Study 14687451 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily dosing of the slow-release formulation
Number of subjects: 0
Study 10740337 — intervention group
Group type: EXPERIMENTAL
Intervention: Early placental drainage plus cord traction
Number of subjects: 477
Study 10740337 — intervention group
Group type: COMPARATOR
Intervention: Expectant delivery (Control)
Number of subjects: 477
Study 9043262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular risk reduction program (5 sessions of 40 minutes each on heart physiology, smoking, hypertension, diet, and physical activity)
Number of subjects: 98
Study 9043262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular risk reduction program
Number of subjects: 98
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: PEN/AMG
Number of subjects: 1573
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: CEPH/AMG
Number of subjects: 1573
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: PEN/CEPH
Number of subjects: 1573
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: Total response rate (Phase I)
Number of subjects: 1573
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: PEN/CEPH/vancomycin
Number of subjects: 1573
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: PEN/CEPH/AMG
Number of subjects: 1573
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: Total response rate (Phase II)
Number of subjects: 1573
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin
Number of subjects: 1573
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: Total response rate (Phase III)
Number of subjects: 1573
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cured patients with unexplained fever (all phases)
Number of subjects: 1573
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with gram-positive bacteremia
Number of subjects: 1573
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with gram-negative organisms
Number of subjects: 1573
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with fungemia
Number of subjects: 1573
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lung infiltrates
Number of subjects: 1573
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically documented infections
Number of subjects: 1573
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically and microbiologically documented infections
Number of subjects: 1573
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocytes rising above 500/mu during infection
Number of subjects: 1573
Study 7948312 — intervention group
Group type: EXPERIMENTAL
Intervention: Documented infections
Number of subjects: 1573
Study 2895705 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 20
Study 2895705 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam 1 mg
Number of subjects: 20
Study 28623414 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenotomy
Number of subjects: 69
Study 28623414 — intervention group
Group type: COMPARATOR
Intervention: Tenodesis
Number of subjects: 69
Study 26546386 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii IGC, 5 days of twice daily, 20‐30 min of exercise
Number of subjects: 22
Study 26546386 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation exercise therapy
Number of subjects: 22
Study 25899452 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 2322
Study 24434382 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice a day)
Number of subjects: 39
Study 24434382 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (250 mg twice a day)
Number of subjects: 39
Study 22067763 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 91-day extended regimen of 100 mcg levonorgestrel/20 mcg ethinyl estradiol (LNG/EE; 84 days)+10 mcg EE (7 days)
Number of subjects: 1736
Study 22067763 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1736
Study 20038723 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 1466
Study 20038723 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1466
Study 20038723 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib and Docetaxel
Number of subjects: 1466
Study 17869973 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (brain temperature maintained at 33 degrees C to 35 degrees C for 4 days)
Number of subjects: 80
Study 17869973 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 80
Study 15741851 — intervention group
Group type: EXPERIMENTAL
Intervention: HI60
Number of subjects: 54
Study 15741851 — intervention group
Group type: EXPERIMENTAL
Intervention: HI30
Number of subjects: 54
Study 12138303 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (20 min, 20 Hz, 20 x 2 s trains, intensity 80% of motor threshold)
Number of subjects: 12
Study 12138303 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (sequence‐controlled cross‐over design)
Number of subjects: 12
Study 10065682 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose erythromycin (500 mg b.i.d.) for 8 weeks
Number of subjects: 21
Study 10065682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8828358 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb (1.0g administered orally)
Number of subjects: 38
Study 1562756 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldose reductase inhibitors
Number of subjects: 0
Study 2866097 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 8
Study 30676350 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive body temperature management (nasopharyngeal temperature ≥36°C)
Number of subjects: 70
Study 30676350 — intervention group
Group type: COMPARATOR
Intervention: Standard body temperature management
Number of subjects: 70
Study 30676350 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive body temperature management
Number of subjects: 70
Study 29327047 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey gel
Number of subjects: 30
Study 29327047 — intervention group
Group type: COMPARATOR
Intervention: Conventional eardrops
Number of subjects: 30
Study 26078115 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TDF HIV pre-exposure prophylaxis (PrEP)
Number of subjects: 296
Study 25285367 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafluprost
Number of subjects: 50
Study 25285367 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 50
Study 22689317 — intervention group
Group type: EXPERIMENTAL
Intervention: S100A12
Number of subjects: 188
Study 22689317 — intervention group
Group type: EXPERIMENTAL
Intervention: MRP8/14
Number of subjects: 188
Study 22689317 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 188
Study 19945274 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural technique
Number of subjects: 0
Study 19945274 — intervention group
Group type: COMPARATOR
Intervention: High-dose epidural (0.25% bupivacaine)
Number of subjects: 0
Study 19945274 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose infusion
Number of subjects: 0
Study 19945274 — intervention group
Group type: COMPARATOR
Intervention: Non-epidural comparison group
Number of subjects: 0
Study 18018435 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training (RMT)
Number of subjects: 14
Study 18018435 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 14
Study 16283275 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral gemfibrozil twice daily for 2 days
Number of subjects: 10
Study 16283275 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral gemfibrozil
Number of subjects: 10
Study 12388962 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (25 micrograms every 4 hours up to six doses)
Number of subjects: 200
Study 12388962 — intervention group
Group type: COMPARATOR
Intervention: Extra-amniotic saline solution infusion with oxytocin
Number of subjects: 200
Study 12388962 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 200
Study 12388962 — intervention group
Group type: COMPARATOR
Intervention: Extra-amniotic saline solution infusion
Number of subjects: 200
Study 9972765 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia (TEA) with bupivacaine 0.5%
Number of subjects: 30
Study 9972765 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study 9972765 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 30
Study 9972765 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 7751531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray (IB) 84 micrograms (two sprays of a 0.06% solution in buffered saline solution)
Number of subjects: 0
Study 7751531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray (IB) 42 micrograms per nostril
Number of subjects: 0
Study 7751531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray (IB) 168 micrograms per nostril
Number of subjects: 0
Study 7751531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray (IB) 84 micrograms per nostril
Number of subjects: 0
Study 7751531 — intervention group
Group type: COMPARATOR
Intervention: Vehicle or no treatment
Number of subjects: 0
Study 1555344 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinged cast brace
Number of subjects: 28
Study 1555344 — intervention group
Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 28
Study 1555344 — intervention group
Group type: EXPERIMENTAL
Intervention: Overcorrected knees
Number of subjects: 28
Study 6587757 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (10 mg thrice daily)
Number of subjects: 56
Study 6587757 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg thrice daily)
Number of subjects: 56
Study 6587757 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg thrice daily)
Number of subjects: 56
Study 6587757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 30278429 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 g/d ALA plus 190 mg/d quercetin
Number of subjects: 67
Study 30278429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 29194917 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (once-weekly extended-release subcutaneous)
Number of subjects: 28
Study 29194917 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 28
Study 26826782 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual design (ABC flap)
Number of subjects: 238
Study 26826782 — intervention group
Group type: COMPARATOR
Intervention: Common design flap
Number of subjects: 238
Study 25201358 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX (oxaliplatin 85 mg/m(2), leucovorin 200 mg/m(2), and fluorouracil bolus 400 mg/m(2) on day 1, and fluorouracil infusion 2400 mg/m(2) for 46 h, every 2 weeks)
Number of subjects: 321
Study 25201358 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil and leucovorin (fluorouracil 380 mg/m(2) and leucovorin 20 mg/m(2) on days 1-5, every 4 weeks)
Number of subjects: 321
Study 25201358 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 321
Study 25201358 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil and leucovorin
Number of subjects: 321
Study 23128768 — intervention group
Group type: EXPERIMENTAL
Intervention: Soothe/Sleep intervention
Number of subjects: 0